A novel mathematical model quantifying drug release from lipid implants.

A novel mathematical theory is presented allowing for a quantitative description of the various mass transport processes involved in the control of drug (in particular protein) release from lipid implants. Importantly, the model takes into account the simultaneous diffusion of multiple compounds, including the drug and water-soluble excipients, such as release modifiers (e.g., PEG) and drug stabilizers (e.g., HP-beta-CD). Also dynamic changes of the implant structure resulting from drug and excipient leaching into the release medium are considered, resulting in a significant time- and position-dependent mobility of the diffusing species within the systems. Furthermore, the limited solubility of the drug and/or excipients under the given conditions in water-filled channels within the implants can be considered. This includes for instance the limited solubility of IFN-alpha in the presence of dissolved PEG. Importantly, good agreement between the novel theory and experimentally determined protein, PEG and HP-beta-CD release kinetics from tristearin-based implants was obtained. In this particular case it could be shown that the precipitation effect of PEG on IFN-alpha in water-filled pores plays a crucial role for the overall control of protein release. Neglecting this phenomenon and assuming constant apparent diffusion coefficients, significant deviations between theory and experiment are observed. Importantly, the novel mathematical theory also allows for a quantitative prediction of the effects of different formulation and processing parameters on the resulting drug release kinetics. For instance the importance of the initial PEG content of the systems for the resulting IFN-alpha release kinetics could be successfully predicted. Interestingly, independent experiments confirmed the theoretical predictions and, thus, proved the validity and suitability of the mathematical theory.

[1]  A. Göpferich,et al.  Acylation of peptides by lactic acid solutions. , 2003, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[2]  Y. Ogawa,et al.  Novel sustained-release dosage forms of proteins using polyglycerol esters of fatty acids. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[3]  Juergen Siepmann,et al.  Mechanisms controlling protein release from lipidic implants: effects of PEG addition. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[4]  Lei Li,et al.  Mapping neutral microclimate pH in PLGA microspheres. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[5]  T. Blunk,et al.  Biocompatibility and erosion behavior of implants made of triglycerides and blends with cholesterol and phospholipids. , 2006, International journal of pharmaceutics.

[6]  P. Odegard,et al.  Inhaled dry powder insulin for the treatment of diabetes mellitus. , 2007, Clinical therapeutics.

[7]  Juergen Siepmann,et al.  New Insight into the Role of Polyethylene Glycol Acting as Protein Release Modifier in Lipidic Implants , 2007, Pharmaceutical Research.

[8]  Divakar,et al.  A modified colorimetric method for the estimation of β‐cyclodextrin using phenolphthalein , 1998 .

[9]  Prolonged Release of Insulin by Cholesterol-Matrix Implant , 1987, Diabetes.

[10]  P. Ghosh,et al.  A colorimetric assay for estimation of polyethylene glycol and polyethylene glycolated protein using ammonium ferrothiocyanate. , 1996, Analytical biochemistry.

[11]  P. Y. Wang,et al.  Palmitic acid as an excipient in implants for sustained release of insulin. , 1991, Biomaterials.

[12]  H. Benson,et al.  Biodegradable implants for the delivery of veterinary vaccines: design, manufacture and antibody responses in sheep. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[13]  J. Siepmann,et al.  Drug release from lipid-based implants: elucidation of the underlying mass transport mechanisms. , 2006, International journal of pharmaceutics.

[14]  G. Winter,et al.  Continuous release of rh-interferon α-2a from triglyceride matrices , 2004 .

[15]  K. Mäder,et al.  pH and Osmotic Pressure Inside Biodegradable Microspheres During Erosion1 , 1999, Pharmaceutical Research.

[16]  Jean-Maurice Vergnaud,et al.  Controlled Drug Release Of Oral Dosage Forms , 1993 .

[17]  Paul Y. Wang Lipids as excipient in sustained release insulin implants , 1989 .

[18]  John Crank,et al.  The Mathematics Of Diffusion , 1956 .

[19]  I. Tucker,et al.  A cholesterol implant used as a delivery system to immunize mice with bovine serum albumin , 1993 .

[20]  C. Allen,et al.  In vitro and in vivo characterization of a novel biocompatible polymer-lipid implant system for the sustained delivery of paclitaxel. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[21]  G. Smith,et al.  Numerical Solution of Partial Differential Equations: Finite Difference Methods , 1978 .

[22]  J. Benoit,et al.  In vitro investigation of lipid implants as a controlled release system for interleukin-18. , 2006, International journal of pharmaceutics.

[23]  P. Deluca,et al.  Polymer and microsphere blending to alter the release of a peptide from PLGA microspheres. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[24]  Y. Youn,et al.  Monitoring of peptide acylation inside degrading PLGA microspheres by capillary electrophoresis and MALDI-TOF mass spectrometry. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[25]  J. Benoit,et al.  Effect of GDNF-releasing biodegradable microspheres on the function and the survival of intrastriatal fetal ventral mesencephalic cell grafts. , 2006, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.